Prothena Biosciences Revenue and Competitors

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The Company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (PRX003). Our lead program, NEOD001, is in a global Phase 3 registration clinical trial ? The VITAL Amyloidosis Study. There is also an on-going Phase 1/2 trial. PRX002 is in a Phase 1 multiple ascending dose clinical trial, and PRX003 is in a Phase 1 single ascending dose clinical trial. Prothena's team has a recognized track record both for profound scientific discoveries and for the development of therapeutics that have become leading commercial products in their respective therapeutic categories. Prior to December 2012, Prothena's business operated as part of Elan Corporation, plc. Prothena's business consists of a substantial portion of Elan's former drug discovery business platform. After the separation from Elan and the related distribution of our ordinary shares to Elan's stockholders, our ordinary shares began trading on The Nasdaq Global Market under the symbol ?PRTA?? on December 21, 2012.